

# Nick J Bansback

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3118577/publications.pdf>

Version: 2024-02-01

159  
papers

8,360  
citations

87843

38  
h-index

51562

86  
g-index

160  
all docs

160  
docs citations

160  
times ranked

12583  
citing authors

#	ARTICLE	IF	CITATIONS
1	The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health, 2009, 9, 88.	1.2	2,724
2	A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Medical Care, 2016, 54, 98-105.	1.1	290
3	Measuring and valuing productivity loss due to poor health: A critical review. Social Science and Medicine, 2011, 72, 185-192.	1.8	245
4	Using a discrete choice experiment to estimate health state utility values. Journal of Health Economics, 2012, 31, 306-318.	1.3	194
5	Obesity and overweight in Canada: an updated cost-of-illness study. Obesity Reviews, 2010, 11, 31-40.	3.1	179
6	Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R177.	1.6	175
7	Physician attitudes toward shared decision making: A systematic review. Patient Education and Counseling, 2015, 98, 1046-1057.	1.0	175
8	Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies. PLoS ONE, 2012, 7, e31115.	1.1	166
9	The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ: British Medical Journal, 2011, 343, d7031-d7031.	2.4	162
10	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV, 2016, 3, e510-e520.	2.1	151
11	The Impact of Age-Related Macular Degeneration on Health Status Utility Values. , 2005, 46, 4016.		132
12	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine, 2007, 26, 1237-1254.	0.8	125
13	Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Annals of the Rheumatic Diseases, 2005, 64, 995-1002.	0.5	101
14	Use of network meta-analysis in clinical guidelines. Bulletin of the World Health Organization, 2016, 94, 782-784.	1.5	92
15	Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1212-1218.	0.4	89
16	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. Dermatology, 2009, 219, 209-218.	0.9	87
17	Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. Annals of Internal Medicine, 2009, 151, 612.	2.0	86
18	Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. Arthritis and Rheumatism, 2008, 58, 939-946.	6.7	82

#	ARTICLE	IF	CITATIONS
19	Economic evaluation of systemic therapies for moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1264-1272.	1.4	73
20	Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. <i>Quality of Life Research</i> , 2007, 16, 533-543.	1.5	71
21	Multiple treatment comparison meta-analyses: a step forward into complexity. <i>Clinical Epidemiology</i> , 2011, 3, 193.	1.5	71
22	Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. <i>BMJ Open</i> , 2017, 7, e014719.	0.8	71
23	Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 963-971.	6.7	68
24	An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. <i>Drugs</i> , 2005, 65, 473-496.	4.9	65
25	Binary Choice Health State Valuation and Mode of Administration: Head-to-Head Comparison of Online and CAPI. <i>Value in Health</i> , 2013, 16, 104-113.	0.1	61
26	Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	1.5	61
27	Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1654-1663.	0.6	60
28	The Effect of OSA on Work Disability and Work-Related Injuries. <i>Chest</i> , 2015, 147, 1422-1428.	0.4	58
29	Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. <i>Rheumatology</i> , 2012, 51, 375-384.	0.9	57
30	Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis. <i>Value in Health</i> , 2012, 15, 46-54.	0.1	54
31	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020, 28, 100573.	3.2	54
32	Measuring Time Input Loss Among Patients With Rheumatoid Arthritis. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 530-536.	0.9	52
33	The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. <i>Journal of Rheumatology</i> , 2008, 35, 592-602.	1.0	52
34	The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. <i>Quality of Life Research</i> , 2009, 18, 1195-205.	1.5	51
35	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014, 18, vii-xxvi, 1-191.	1.3	47
36	Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2017, 167, 8.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 176-187.	1.0	45
38	Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 631-639.	0.9	44
39	Decentralized Automated Dispensing Devices: Systematic Review of Clinical and Economic Impacts in Hospitals. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 138-48.	0.1	44
40	Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration. <i>Medical Care</i> , 2020, 58, 566-573.	1.1	42
41	A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly. <i>Value in Health</i> , 2017, 20, 404-411.	0.1	41
42	Testing a discrete choice experiment including duration to value health states for large descriptive systems: Addressing design and sampling issues. <i>Social Science and Medicine</i> , 2014, 114, 38-48.	1.8	39
43	Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. <i>Current Rheumatology Reports</i> , 2016, 18, 51.	2.1	39
44	Bar Code Medication Administration Technology: A Systematic Review of Impact on Patient Safety When Used with Computerized Prescriber Order Entry and Automated Dispensing Devices. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 394-402.	0.1	38
45	DECIDE: a Decision Support Tool to Facilitate Parents' Choices Regarding Genome-Wide Sequencing. <i>Journal of Genetic Counseling</i> , 2016, 25, 1298-1308.	0.9	36
46	Work disability rates in RA. Results from an inception cohort with 24 years follow-up. <i>Rheumatology</i> , 2012, 51, 385-392.	0.9	35
47	Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. <i>Rheumatology</i> , 2015, 54, 1816-1825.	0.9	35
48	Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 1615-1622.	0.6	34
49	Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. <i>Addiction</i> , 2018, 113, 1264-1273.	1.7	33
50	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011, 22, 65-74.	1.1	32
51	The cost-effectiveness of patient decision aids: A systematic review. <i>Healthcare</i> , 2014, 2, 251-257.	0.6	32
52	Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review. <i>Patient Education and Counseling</i> , 2016, 99, 491-500.	1.0	31
53	Seeking control in the midst of uncertainty: Women's experiences of choosing mode of birth after caesarean. <i>Women and Birth</i> , 2017, 30, 129-136.	0.9	31
54	An individualized patient-reported outcome measure (PROM) based patient decision aid and surgeon report for patients considering total knee arthroplasty: protocol for a pragmatic randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 89.	0.8	31

#	ARTICLE	IF	CITATIONS
55	Respondent Understanding in Discrete Choice Experiments: A Scoping Review. <i>Patient</i> , 2021, 14, 17-53.	1.1	31
56	Development of a population-based microsimulation model of osteoarthritis in Canada. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 303-311.	0.6	30
57	The burden of nonadherence among adults with asthma: a role for shared decision-making. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 705-712.	2.7	30
58	Impact of Inflammatory Bowel Disease on Disability. <i>Current Gastroenterology Reports</i> , 2014, 16, 414.	1.1	29
59	Exclusion Criteria in National Health State Valuation Studies. <i>Medical Decision Making</i> , 2016, 36, 798-810.	1.2	29
60	Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive study. <i>Thrombosis Research</i> , 2019, 173, 109-116.	0.8	29
61	Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. <i>Eye</i> , 2007, 21, 1455-1463.	1.1	28
62	Why Do Patients with Inflammatory Arthritis Often Score States "Worse than Death" on the EQ-5D? An Investigation of the EQ-5D Classification System. <i>Value in Health</i> , 2009, 12, 1026-1034.	0.1	28
63	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 21.	1.0	28
64	Long-Term Effectiveness of Oral Appliance versus CPAP Therapy and the Emerging Importance of Understanding Patient Preferences. <i>Sleep</i> , 2013, 36, 1271-1272.	0.6	28
65	Economic Evaluations in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2008, 26, 395-408.	1.7	27
66	Need for Speed: An Efficient Algorithm for Calculation of Single-Parameter Expected Value of Partial Perfect Information. <i>Value in Health</i> , 2013, 16, 438-448.	0.1	27
67	Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2016, 25, 1679-1685.	1.5	27
68	Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences. <i>Medical Decision Making</i> , 2017, 37, 285-297.	1.2	27
69	Do Women Have a Choice? Care Providers' and Decision Makers' Perspectives on Barriers to Access of Health Services for Birth after a Previous Cesarean. <i>Birth</i> , 2017, 44, 153-160.	1.1	27
70	Statin Therapy in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2009, 27, 25-37.	1.7	26
71	Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1761-1764.	0.5	26
72	Assessing an Interactive Online Tool to Support Parents' Genomic Testing Decisions. <i>Journal of Genetic Counseling</i> , 2019, 28, 10-17.	0.9	26

#	ARTICLE	IF	CITATIONS
73	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. PLoS ONE, 2019, 14, e0216075.	1.1	25
74	Health state utility values: A description of their development and application for rheumatic diseases. Arthritis and Rheumatism, 2008, 59, 1018-1026.	6.7	24
75	Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?. Medical Decision Making, 2016, 36, 490-502.	1.2	24
76	Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey. Patient, 2015, 8, 93-101.	1.1	22
77	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. Value in Health, 2017, 20, 969-975.	0.1	22
78	The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 357-366.	1.6	22
79	Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia. Canadian Journal of Neurological Sciences, 2009, 36, 735-739.	0.3	21
80	Communicating Uncertainty in Benefits and Harms: A Review of Patient Decision Support Interventions. Patient, 2017, 10, 311-319.	1.1	21
81	Testing and treatment for obstructive sleep apnea in Canada: funding models must change. Cmaj, 2017, 189, E1524-E1528.	0.9	21
82	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1729-36.	1.0	21
83	Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology, 2007, 47, 119-120.	0.9	20
84	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 9-18.	1.0	20
85	Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision) Tj ETQq1 1 0.784314 rgBT /Overlock Decision Making, 2014, 14, 62.	1.5	20
86	The Sheffield rheumatoid arthritis health economic model. Rheumatology, 2011, 50, iv26-iv31.	0.9	19
87	Impact of the recall period on measuring health utilities for acute events. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Overlock 18	0.8	18
88	Exploiting order effects to improve the quality of decisions. Patient Education and Counseling, 2014, 96, 197-203.	1.0	18
89	The economics of treatment in early rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 83-92.	1.4	17
90	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharmaceutical Statistics, 2009, 8, 371-389.	0.7	16

#	ARTICLE	IF	CITATIONS
91	Development of a patient decision aid prototype for adults with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2016, 20, 653-661.	0.9	16
92	A measurement framework for adherence in patient decision aid trials applied in a systematic review subanalysis. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 15-23.	2.4	16
93	Evaluating Canadians'™ Values for Drug Coverage Decision Making. <i>Value in Health</i> , 2019, 22, 362-369.	0.1	16
94	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. <i>Clinical Rheumatology</i> , 2020, 39, 2931-2941.	1.0	15
95	Costs of early spondyloarthritis: estimates from the first 3â€¦years of the DESIR cohort. <i>RMD Open</i> , 2016, 2, e000230.	1.8	14
96	Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists. <i>Journal of Rheumatology</i> , 2011, 38, 1770-1775.	1.0	13
97	Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study. <i>RMD Open</i> , 2015, 1, e000042-e000042.	1.8	13
98	An online individualised patient decision aid improves the quality of decisions in patients considering total knee arthroplasty in routine care: A randomized controlled trial. <i>Osteoarthritis and Cartilage Open</i> , 2022, 4, 100286.	0.9	13
99	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. <i>Journal of Rheumatology</i> , 2017, 44, 1899-1903.	1.0	12
100	Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. <i>BMC Neurology</i> , 2019, 19, 173.	0.8	12
101	&lt;p>&gt;Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study&lt;p>&gt; Patient Preference and Adherence, 2020, Volume 14, 829-838.	0.8	12
102	A prognostic model for functional outcome in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1503-10.	1.0	12
103	Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 382-391.	0.9	11
104	Recognizing difficult trade-offs: values and treatment preferences for end-of-life care in a multi-site survey of adult patients in family practices. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 164.	1.5	11
105	Support Tools for Preference-Sensitive Decisions in Healthcare: Where Are We? Where Do We Go? How Do We Get There?. <i>Patient</i> , 2019, 12, 439-443.	1.1	11
106	Manipulating the 5 Dimensions of the EuroQol Instrument: The Effects on Self-Reporting Actual Health and Valuing Hypothetical Health States. <i>Medical Decision Making</i> , 2019, 39, 380-392.	1.2	11
107	Communicating uncertainty in cancer prognosis: A review of web-based prognostic tools. <i>Patient Education and Counseling</i> , 2019, 102, 842-849.	1.0	11
108	Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference Study. <i>Canadian Journal of Cardiology</i> , 2020, 36, 775-779.	0.8	11

#	ARTICLE	IF	CITATIONS
109	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. <i>Quality of Life Research</i> , 2009, 18, 815-824.	1.5	10
110	Assessing adherence with phototherapy protocols. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1259-1261.	0.6	10
111	Development and pilot testing of a tool to calculate parental and societal costs of raising a child with intellectual disability. <i>Journal of Intellectual and Developmental Disability</i> , 2016, 41, 11-20.	1.1	10
112	Preferences for "New" Treatments Diminish in the Face of Ambiguity. <i>Health Economics (United Kingdom)</i> 2010, 25, 1079-1098.	0.8	10
113	The Effect of Direct-to-Consumer Genetic Tests on Anticipated Affect and Health-Seeking Behaviors: A Pilot Survey. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 1165-1171.	0.3	9
114	The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 659-676.	1.4	9
115	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. <i>Medical Decision Making</i> , 2015, 35, 671-682.	1.2	9
116	Attitude to health risk in the Canadian population: a cross-sectional survey. <i>CMAJ Open</i> , 2016, 4, E284-E291.	1.1	9
117	Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis. <i>Current Rheumatology Reports</i> , 2017, 19, 54.	2.1	9
118	How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?. <i>Medical Decision Making</i> , 2018, 38, 306-318.	1.2	9
119	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. <i>Pharmaceutical Statistics</i> , 2009, 8, 150-162.	0.7	8
120	How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?. <i>Current Rheumatology Reports</i> , 2015, 17, 514.	2.1	8
121	Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771644.	0.5	8
122	Patterns of Tumor Necrosis Factor Inhibitor ( TNF i) Biosimilar Use Across United States Rheumatology Practices. <i>ACR Open Rheumatology</i> , 2020, 2, 79-83.	0.9	8
123	Development of an Implementation Strategy for Patient Decision Aids in Rheumatoid Arthritis Through Application of the Behavior Change Wheel. <i>ACR Open Rheumatology</i> , 2021, 3, 312-323.	0.9	8
124	Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study. <i>Rheumatology International</i> , 2021, , 1.	1.5	8
125	An update on the measurement of productivity losses due to rheumatoid diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 585-597.	1.4	7
126	How different are composite and traditional TTO valuations of severe EQ-5D-5L states?. <i>Quality of Life Research</i> , 2016, 25, 2101-2108.	1.5	7



#	ARTICLE	IF	CITATIONS
127	Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 7-19.	0.6	7
128	Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. <i>Medical Decision Making</i> , 2020, 40, 1003-1019.	1.2	7
129	When does the use of individual patient data in network meta-analysis make a difference? A simulation study. <i>BMC Medical Research Methodology</i> , 2021, 21, 21.	1.4	7
130	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 919-924.	1.6	7
131	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 519-529.	0.7	6
132	Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. <i>RMD Open</i> , 2019, 5, e000872.	1.8	6
133	Patient-provider communication about medication cost in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 93-100.	1.0	6
134	Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1178-83.	1.0	6
135	Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study. <i>RMD Open</i> , 2016, 2, e000222.	1.8	5
136	Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2017, 26, 1483-1492.	1.5	5
137	Validation of a novel diabetic retinopathy utility index using discrete choice experiments. <i>British Journal of Ophthalmology</i> , 2020, 104, 188-193.	2.1	5
138	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. <i>Cmaj</i> , 2022, 194, E556-E560.	0.9	5
139	Cost-effectiveness of tumor necrosis factor- $\alpha$ antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 155-169.	0.7	4
140	Now that we know what's BeSt, what is good value for the money?. <i>Arthritis and Rheumatism</i> , 2009, 61, 289-290.	6.7	4
141	Optimal timing of influenza vaccination in patients with human immunodeficiency virus: A Markov cohort model based on serial study participant hemoagglutination inhibition titers. <i>Vaccine</i> , 2014, 32, 677-684.	1.7	4
142	Implausible States: Prevalence of EQ-5D-5L States in the General Population and Its Effect on Health State Valuation. <i>Medical Decision Making</i> , 2020, 40, 735-745.	1.2	4
143	Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal Study. <i>ACR Open Rheumatology</i> , 2020, 2, 648-656.	0.9	4
144	Making smart investment decisions in clinical research. <i>Trials</i> , 2015, 16, 590.	0.7	3

#	ARTICLE	IF	CITATIONS
145	Surgical assessment: measuring unobserved health. BMC Surgery, 2015, 15, 4.	0.6	3
146	Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. Cost Effectiveness and Resource Allocation, 2017, 15, 20.	0.6	3
147	Patients'™ Experiences and Priorities for Accessing Gastroenterology Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, 3-9.	0.1	2
148	Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART. BMC Medical Research Methodology, 2021, 21, 60.	1.4	2
149	Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients. Patient, 2021, , 1.	1.1	2
150	Estimation of a Canadian preference-based scoring algorithm for the Veterans RAND 12-Item Health Survey: a population survey using a discrete-choice experiment. CMAJ Open, 2022, 10, E589-E598.	1.1	2
151	Response to "Marginal Costs of Hospital-Acquired Conditions: Information for Priority-Setting for Patient Safety Programmes and Research"™, Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6. Journal of Health Services Research and Policy, 2012, 17, 127-127.	0.8	1
152	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. Journal of Rheumatology, 2017, 44, 1436-1444.	1.0	1
153	<p>Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative Study</p>. Patient Preference and Adherence, 2020, Volume 14, 2105-2121.	0.8	1
154	The Patient's or Society's: Whose Quality of Life is it Anyway?. Sleep, 2014, 37, 1885-1886.	0.6	0
155	Improving patient-centred care for rheumatoid arthritis. Cmaj, 2016, 188, 999-1000.	0.9	0
156	Moving from outcomes to values to deliver high-quality health care"™A new checklist for valuation studies. Journal of Clinical Epidemiology, 2017, 83, 3-5.	2.4	0
157	Patient-Oriented Research from the ISDM 2019 Conference: A Legacy Now More Relevant Than Ever. Patient, 2020, 13, 649-652.	1.1	0
158	Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110299.	0.5	0
159	An economic valuation technique identified different inpatient care experience as priorities for older Canadians than a traditional approach. Journal of Clinical Epidemiology, 2021, 139, 1-11.	2.4	0